Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 140 entries
Sorted by: Best Match Show Resources per page
Common, germline genetic variations in the novel tumor suppressor .

Oncotarget

Lin M, Zhang L, Hildebrandt MAT, Huang M, Wu X, Ye Y.
PMID: 29088836
Oncotarget. 2017 Aug 24;8(43):74936-74946. doi: 10.18632/oncotarget.20465. eCollection 2017 Sep 26.

BRCA1 associated protein-1 (BAP1) is a novel tumor suppressor that has recently been shown to be somatically mutated in several cancers. The

Cite
Lin M, Zhang L, Hildebrandt MAT, et al. Common, germline genetic variations in the novel tumor suppressor . Oncotarget. 2017;8(43):74936-74946doi: 10.18632/oncotarget.20465.
Lin, M., Zhang, L., Hildebrandt, M. A. T., Huang, M., Wu, X., & Ye, Y. (2017). Common, germline genetic variations in the novel tumor suppressor . Oncotarget, 8(43), 74936-74946. https://doi.org/10.18632/oncotarget.20465
Lin, Moubin, et al. "Common, germline genetic variations in the novel tumor suppressor ." Oncotarget vol. 8,43 (2017): 74936-74946. doi: https://doi.org/10.18632/oncotarget.20465
Lin M, Zhang L, Hildebrandt MAT, Huang M, Wu X, Ye Y. Common, germline genetic variations in the novel tumor suppressor . Oncotarget. 2017 Aug 24;8(43):74936-74946. doi: 10.18632/oncotarget.20465. eCollection 2017 Sep 26. PMID: 29088836; PMCID: PMC5650391.
Copy Download .nbib Format: NLM
A Multi-Camera System for Bioluminescence Tomography in Preclinical Oncology Research.

Diagnostics (Basel, Switzerland)

Lewis MA, Richer E, Slavine NV, Kodibagkar VD, Soesbe TC, Antich PP, Mason RP.
PMID: 26824926
Diagnostics (Basel). 2013 Jul 09;3(3):325-43. doi: 10.3390/diagnostics3030325.

Bioluminescent imaging (BLI) of cells expressing luciferase is a valuable noninvasive technique for investigating molecular events and tumor dynamics in the living animal. Current usage is often limited to planar imaging, but tomographic imaging can enhance the usefulness of...

Cite
Lewis MA, Richer E, Slavine NV, et al. A Multi-Camera System for Bioluminescence Tomography in Preclinical Oncology Research. Diagnostics (Basel). 2013;3(3):325-43doi: 10.3390/diagnostics3030325.
Lewis, M. A., Richer, E., Slavine, N. V., Kodibagkar, V. D., Soesbe, T. C., Antich, P. P., & Mason, R. P. (2013). A Multi-Camera System for Bioluminescence Tomography in Preclinical Oncology Research. Diagnostics (Basel, Switzerland), 3(3), 325-43. https://doi.org/10.3390/diagnostics3030325
Lewis, Matthew A, et al. "A Multi-Camera System for Bioluminescence Tomography in Preclinical Oncology Research." Diagnostics (Basel, Switzerland) vol. 3,3 (2013): 325-43. doi: https://doi.org/10.3390/diagnostics3030325
Lewis MA, Richer E, Slavine NV, Kodibagkar VD, Soesbe TC, Antich PP, Mason RP. A Multi-Camera System for Bioluminescence Tomography in Preclinical Oncology Research. Diagnostics (Basel). 2013 Jul 09;3(3):325-43. doi: 10.3390/diagnostics3030325. PMID: 26824926; PMCID: PMC4665465.
Copy Download .nbib Format: NLM
Data-mining analysis suggests an epigenetic pathogenesis for type 2 diabetes.

Journal of biomedicine & biotechnology

Wren JD, Garner HR.
PMID: 16046815
J Biomed Biotechnol. 2005 Jun 30;2005(2):104-12. doi: 10.1155/JBB.2005.104.

The etiological origin of type 2 diabetes mellitus (T2DM) has long been controversial. The body of literature related to T2DM is vast and varied in focus, making a broad epidemiological perspective difficult, if not impossible. A data-mining approach was...

Cite
Wren JD, Garner HR. Data-mining analysis suggests an epigenetic pathogenesis for type 2 diabetes. J Biomed Biotechnol. 2005;2005(2):104-12doi: 10.1155/JBB.2005.104.
Wren, J. D., & Garner, H. R. (2005). Data-mining analysis suggests an epigenetic pathogenesis for type 2 diabetes. Journal of biomedicine & biotechnology, 2005(2), 104-12. https://doi.org/10.1155/JBB.2005.104
Wren, Jonathan D, and Garner, Harold R. "Data-mining analysis suggests an epigenetic pathogenesis for type 2 diabetes." Journal of biomedicine & biotechnology vol. 2005,2 (2005): 104-12. doi: https://doi.org/10.1155/JBB.2005.104
Wren JD, Garner HR. Data-mining analysis suggests an epigenetic pathogenesis for type 2 diabetes. J Biomed Biotechnol. 2005 Jun 30;2005(2):104-12. doi: 10.1155/JBB.2005.104. PMID: 16046815; PMCID: PMC1184044.
Copy Download .nbib Format: NLM
Nonparametric Sample Size Estimation for Sensitivity and Specificity with Multiple Observations per Subject.

Drug information journal

Hu F, Schucany WR, Ahn C.
PMID: 22114363
Drug Inf J. 2010;44(5):609-616. doi: 10.1177/009286151004400508.

We propose a sample size calculation approach for the estimation of sensitivity and specificity of diagnostic tests with multiple observations per subjects. Many diagnostic tests such as diagnostic imaging or periodontal tests are characterized by the presence of multiple...

Cite
Hu F, Schucany WR, Ahn C. Nonparametric Sample Size Estimation for Sensitivity and Specificity with Multiple Observations per Subject. Drug Inf J. 2010;44(5):609-616doi: 10.1177/009286151004400508.
Hu, F., Schucany, W. R., & Ahn, C. (2010). Nonparametric Sample Size Estimation for Sensitivity and Specificity with Multiple Observations per Subject. Drug information journal, 44(5), 609-616. https://doi.org/10.1177/009286151004400508
Hu, Fan, et al. "Nonparametric Sample Size Estimation for Sensitivity and Specificity with Multiple Observations per Subject." Drug information journal vol. 44,5 (2010): 609-616. doi: https://doi.org/10.1177/009286151004400508
Hu F, Schucany WR, Ahn C. Nonparametric Sample Size Estimation for Sensitivity and Specificity with Multiple Observations per Subject. Drug Inf J. 2010;44(5):609-616. doi: 10.1177/009286151004400508. PMID: 22114363; PMCID: PMC3221312.
Copy Download .nbib Format: NLM
Tumor oncogenotypes and lung cancer stem cell identity.

Cell stem cell

Sullivan JP, Minna JD.
PMID: 20621039
Cell Stem Cell. 2010 Jul 02;7(1):2-4. doi: 10.1016/j.stem.2010.06.005.

In this issue of Cell Stem Cell, Curtis et. al. (2010) reveal that the identities of lung cancer stem cell populations differ depending on the specific tumor oncogenotype in three murine lung adenocarcinoma models. These findings highlight the importance...

Cite
Sullivan JP, Minna JD. Tumor oncogenotypes and lung cancer stem cell identity. Cell Stem Cell. 2010;7(1):2-4doi: 10.1016/j.stem.2010.06.005.
Sullivan, J. P., & Minna, J. D. (2010). Tumor oncogenotypes and lung cancer stem cell identity. Cell stem cell, 7(1), 2-4. https://doi.org/10.1016/j.stem.2010.06.005
Sullivan, James P, and Minna, John D. "Tumor oncogenotypes and lung cancer stem cell identity." Cell stem cell vol. 7,1 (2010): 2-4. doi: https://doi.org/10.1016/j.stem.2010.06.005
Sullivan JP, Minna JD. Tumor oncogenotypes and lung cancer stem cell identity. Cell Stem Cell. 2010 Jul 02;7(1):2-4. doi: 10.1016/j.stem.2010.06.005. PMID: 20621039; PMCID: PMC3374716.
Copy Download .nbib Format: NLM
Molecular biology of lung cancer.

Journal of thoracic disease

Cooper WA, Lam DC, O'Toole SA, Minna JD.
PMID: 24163741
J Thorac Dis. 2013 Oct;5:S479-90. doi: 10.3978/j.issn.2072-1439.2013.08.03.

Lung cancers are characterised by abundant genetic diversity with relatively few recurrent mutations occurring at high frequency. However, the genetic alterations often affect a common group of oncogenic signalling pathways. There have been vast improvements in our understanding of...

Cite
Cooper WA, Lam DC, O'Toole SA, et al. Molecular biology of lung cancer. J Thorac Dis. 2013;5:S479-90doi: 10.3978/j.issn.2072-1439.2013.08.03.
Cooper, W. A., Lam, D. C., O'Toole, S. A., & Minna, J. D. (2013). Molecular biology of lung cancer. Journal of thoracic disease, 5S479-90. https://doi.org/10.3978/j.issn.2072-1439.2013.08.03
Cooper, Wendy A, et al. "Molecular biology of lung cancer." Journal of thoracic disease vol. 5 (2013): S479-90. doi: https://doi.org/10.3978/j.issn.2072-1439.2013.08.03
Cooper WA, Lam DC, O'Toole SA, Minna JD. Molecular biology of lung cancer. J Thorac Dis. 2013 Oct;5:S479-90. doi: 10.3978/j.issn.2072-1439.2013.08.03. PMID: 24163741; PMCID: PMC3804875.
Copy Download .nbib Format: NLM
Relative Efficiency of Unequal Versus Equal Cluster Sizes for the Nonparametric Weighted Sign Test Estimators in Clustered Binary Data.

Drug information journal

Ahn C, Hu F, Lee SC.
PMID: 23486929
Drug Inf J. 2012 Jul 02;46(4):428-433. doi: 10.1177/0092861512449818.

We consider analysis of clustered binary data from multiple observations for each subject in which any two observations from a subject are assumed to have a common correlation coefficient. In the weighted sign test on proportion in clustered binary...

Cite
Ahn C, Hu F, Lee SC. Relative Efficiency of Unequal Versus Equal Cluster Sizes for the Nonparametric Weighted Sign Test Estimators in Clustered Binary Data. Drug Inf J. 2012;46(4):428-433doi: 10.1177/0092861512449818.
Ahn, C., Hu, F., & Lee, S. C. (2012). Relative Efficiency of Unequal Versus Equal Cluster Sizes for the Nonparametric Weighted Sign Test Estimators in Clustered Binary Data. Drug information journal, 46(4), 428-433. https://doi.org/10.1177/0092861512449818
Ahn, Chul, et al. "Relative Efficiency of Unequal Versus Equal Cluster Sizes for the Nonparametric Weighted Sign Test Estimators in Clustered Binary Data." Drug information journal vol. 46,4 (2012): 428-433. doi: https://doi.org/10.1177/0092861512449818
Ahn C, Hu F, Lee SC. Relative Efficiency of Unequal Versus Equal Cluster Sizes for the Nonparametric Weighted Sign Test Estimators in Clustered Binary Data. Drug Inf J. 2012 Jul 02;46(4):428-433. doi: 10.1177/0092861512449818. PMID: 23486929; PMCID: PMC3593313.
Copy Download .nbib Format: NLM
Preferential expression of potential markers for cancer stem cells in large cell neuroendocrine carcinoma of the lung. An FFPE proteomic study.

Journal of clinical bioinformatics

Nomura M, Fukuda T, Fujii K, Kawamura T, Tojo H, Kihara M, Bando Y, Gazdar AF, Tsuboi M, Oshiro H, Nagao T, Ohira T, Ikeda N, Gotoh N, Kato H, Marko-Varga G, Nishimura T.
PMID: 21888658
J Clin Bioinforma. 2011 Sep 03;1(1):23. doi: 10.1186/2043-9113-1-23.

BACKGROUND: Large cell neuroendocrine carcinoma (LCNEC) of the lung, a subtype of large cell carcinoma (LCC), is characterized by neuroendocrine differentiation that small cell lung carcinoma (SCLC) shares. Pre-therapeutic histological distinction between LCNEC and SCLC has so far been...

Cite
Nomura M, Fukuda T, Fujii K, et al. Preferential expression of potential markers for cancer stem cells in large cell neuroendocrine carcinoma of the lung. An FFPE proteomic study. J Clin Bioinforma. 2011;1(1):23doi: 10.1186/2043-9113-1-23.
Nomura, M., Fukuda, T., Fujii, K., Kawamura, T., Tojo, H., Kihara, M., Bando, Y., Gazdar, A. F., Tsuboi, M., Oshiro, H., Nagao, T., Ohira, T., Ikeda, N., Gotoh, N., Kato, H., Marko-Varga, G., & Nishimura, T. (2011). Preferential expression of potential markers for cancer stem cells in large cell neuroendocrine carcinoma of the lung. An FFPE proteomic study. Journal of clinical bioinformatics, 1(1), 23. https://doi.org/10.1186/2043-9113-1-23
Nomura, Masaharu, et al. "Preferential expression of potential markers for cancer stem cells in large cell neuroendocrine carcinoma of the lung. An FFPE proteomic study." Journal of clinical bioinformatics vol. 1,1 (2011): 23. doi: https://doi.org/10.1186/2043-9113-1-23
Nomura M, Fukuda T, Fujii K, Kawamura T, Tojo H, Kihara M, Bando Y, Gazdar AF, Tsuboi M, Oshiro H, Nagao T, Ohira T, Ikeda N, Gotoh N, Kato H, Marko-Varga G, Nishimura T. Preferential expression of potential markers for cancer stem cells in large cell neuroendocrine carcinoma of the lung. An FFPE proteomic study. J Clin Bioinforma. 2011 Sep 03;1(1):23. doi: 10.1186/2043-9113-1-23. PMID: 21888658; PMCID: PMC3178477.
Copy Download .nbib Format: NLM
Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer.

Oncotarget

Gomez DR, Byers LA, Nilsson M, Diao L, Wang J, Li L, Tong P, Hofstad M, Saigal B, Wistuba I, Kalhor N, Swisher S, Fan Y, Hong WK, Suraokar M, Behrens C, Moran C, Heymach JV.
PMID: 29581842
Oncotarget. 2018 Jan 30;9(18):14268-14284. doi: 10.18632/oncotarget.24361. eCollection 2018 Mar 06.

While several molecular targets have been identified for adenocarcinoma (ACA) of the lung, similar drivers with squamous cell carcinoma (SCC) are sparse. We compared signaling pathways and potential therapeutic targets in lung SCC and ACA tumors using reverse phase...

Cite
Gomez DR, Byers LA, Nilsson M, et al. Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget. 2018;9(18):14268-14284doi: 10.18632/oncotarget.24361.
Gomez, D. R., Byers, L. A., Nilsson, M., Diao, L., Wang, J., Li, L., Tong, P., Hofstad, M., Saigal, B., Wistuba, I., Kalhor, N., Swisher, S., Fan, Y., Hong, W. K., Suraokar, M., Behrens, C., Moran, C., & Heymach, J. V. (2018). Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget, 9(18), 14268-14284. https://doi.org/10.18632/oncotarget.24361
Gomez, Daniel Richard, et al. "Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer." Oncotarget vol. 9,18 (2018): 14268-14284. doi: https://doi.org/10.18632/oncotarget.24361
Gomez DR, Byers LA, Nilsson M, Diao L, Wang J, Li L, Tong P, Hofstad M, Saigal B, Wistuba I, Kalhor N, Swisher S, Fan Y, Hong WK, Suraokar M, Behrens C, Moran C, Heymach JV. Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget. 2018 Jan 30;9(18):14268-14284. doi: 10.18632/oncotarget.24361. eCollection 2018 Mar 06. PMID: 29581842; PMCID: PMC5865668.
Copy Download .nbib Format: NLM
Probe mapping across multiple microarray platforms.

Briefings in bioinformatics

Allen JD, Wang S, Chen M, Girard L, Minna JD, Xie Y, Xiao G.
PMID: 22199380
Brief Bioinform. 2012 Sep;13(5):547-54. doi: 10.1093/bib/bbr076. Epub 2011 Dec 23.

Access to gene expression data has become increasingly common in recent years; however, analysis has become more difficult as it is often desirable to integrate data from different platforms. Probe mapping across microarray platforms is the first and most...

Cite
Allen JD, Wang S, Chen M, et al. Probe mapping across multiple microarray platforms. Brief Bioinform. 2011;13(5):547-54doi: 10.1093/bib/bbr076.
Allen, J. D., Wang, S., Chen, M., Girard, L., Minna, J. D., Xie, Y., & Xiao, G. (2012). Probe mapping across multiple microarray platforms. Briefings in bioinformatics, 13(5), 547-54. https://doi.org/10.1093/bib/bbr076
Allen, Jeffrey D, et al. "Probe mapping across multiple microarray platforms." Briefings in bioinformatics vol. 13,5 (2012): 547-54. doi: https://doi.org/10.1093/bib/bbr076
Allen JD, Wang S, Chen M, Girard L, Minna JD, Xie Y, Xiao G. Probe mapping across multiple microarray platforms. Brief Bioinform. 2012 Sep;13(5):547-54. doi: 10.1093/bib/bbr076. Epub 2011 Dec 23. PMID: 22199380; PMCID: PMC3431719.
Copy Download .nbib Format: NLM
New targets for controlling Ebola virus disease.

National science review

Qin FX, Jiang CY, Jiang T, Cheng G.
PMID: 26550528
Natl Sci Rev. 2015 Sep;2(3):266-267. doi: 10.1093/nsr/nwv043. Epub 2015 Jul 17.

No abstract available.

Cite
Qin FX, Jiang CY, Jiang T, et al. New targets for controlling Ebola virus disease. Natl Sci Rev. 2015;2(3):266-267doi: 10.1093/nsr/nwv043.
Qin, F. X., Jiang, C. Y., Jiang, T., & Cheng, G. (2015). New targets for controlling Ebola virus disease. National science review, 2(3), 266-267. https://doi.org/10.1093/nsr/nwv043
Qin, F Xiao-Feng, et al. "New targets for controlling Ebola virus disease." National science review vol. 2,3 (2015): 266-267. doi: https://doi.org/10.1093/nsr/nwv043
Qin FX, Jiang CY, Jiang T, Cheng G. New targets for controlling Ebola virus disease. Natl Sci Rev. 2015 Sep;2(3):266-267. doi: 10.1093/nsr/nwv043. Epub 2015 Jul 17. PMID: 26550528; PMCID: PMC4632854.
Copy Download .nbib Format: NLM
Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer.

Cancer informatics

Wang T, Lu R, Lai S, Schiller JH, Zhou FL, Ci B, Wang S, Gao X, Yao B, Gerber DE, Johnson DH, Xiao G, Xie Y.
PMID: 31057324
Cancer Inform. 2019 Apr 05;18:1176935119837547. doi: 10.1177/1176935119837547. eCollection 2019.

IMPORTANCE: Nomogram prognostic models can facilitate cancer patient treatment plans and patient enrollment in clinical trials.OBJECTIVE: The primary objective is to provide an updated and accurate prognostic model for predicting the survival of advanced non-small-cell lung cancer (NSCLC) patients,...

Cite
Wang T, Lu R, Lai S, et al. Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer. Cancer Inform. 2019;18:1176935119837547doi: 10.1177/1176935119837547.
Wang, T., Lu, R., Lai, S., Schiller, J. H., Zhou, F. L., Ci, B., Wang, S., Gao, X., Yao, B., Gerber, D. E., Johnson, D. H., Xiao, G., & Xie, Y. (2019). Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer. Cancer informatics, 181176935119837547. https://doi.org/10.1177/1176935119837547
Wang, Tao, et al. "Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer." Cancer informatics vol. 18 (2019): 1176935119837547. doi: https://doi.org/10.1177/1176935119837547
Wang T, Lu R, Lai S, Schiller JH, Zhou FL, Ci B, Wang S, Gao X, Yao B, Gerber DE, Johnson DH, Xiao G, Xie Y. Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer. Cancer Inform. 2019 Apr 05;18:1176935119837547. doi: 10.1177/1176935119837547. eCollection 2019. PMID: 31057324; PMCID: PMC6452590.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 140 entries